期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

表观遗传学药物FK228联合氟尿嘧啶对肝癌细胞增殖、凋亡及Fas mRNA表达的影响 被引量：2

Effect of fluorouracil combined with FK228 on the proliferation,apoptosis and Fas mRNA level in HepG2 hepatoma cell lines
下载PDF
导出
摘要 目的:探讨表观遗传学药物FK228联合氟尿嘧啶(fluorouracil,FU)对肝癌细胞株增殖、凋亡及FasmRNA表达水平的影响。方法:本实验分为正常对照组、FK228处理组、FU处理组和FK228联合FU处理组。用四甲基偶氮唑蓝法检测FK228和FU单药及联合用药对HepG2肝癌细胞增殖的影响,分别以金氏公式Q值法和多因素方差分析法分析两药联合效应;流式细胞术检测细胞凋亡率;RT-PCR法检测Fas mRNA表达。结果:FK228及FU均可抑制HepG2增殖,并呈时间和剂量依赖性;FK228联合FU处理组与相应浓度的FU单药组相比,细胞抑制率明显升高(P<0.05),Q值均大于1,两药呈现交互效应,两药有协同作用;与FK228处理组和FU处理组比较,联合用药组细胞凋亡率明显升高(P<0.05),Fas mRNA表达明显上调(P<0.05)。结论:FK228能增强5-FU对肝癌细胞的增殖抑制和凋亡诱导,上调Fas mRNA表达水平,提高肝癌细胞对5-FU的敏感性。 Objective To explore the effect of fluorouracil(FU) combined with epigenetic drug FK228(depsipeptide FR901228) on the proliferation,apoptosis and Fas mRNA level in HepG2 hepatoma cell lines.Methods There were 4 groups in this experiment: an untreated group,an FK228 treated group,a FU treated group,and a FU combined with FK228 group.Tetrazolium salt colorimetry(MTT) assay was used to assess the cell inhibition rate.Q value of King s formula and multi-factor analysis of variance(ANOVA) were used to judge the ...
作者 陈忠南 徐克前
机构地区 中南大学湘雅医学院医学检验系 湖南省结核病医院检验科
出处 《中南大学学报（医学版）》 CAS CSCD 北大核心 2009年第2期124-129,共6页 Journal of Central South University ：Medical Science
关键词 FK228 氟尿嘧啶 肝癌细胞 细胞凋亡 FAS fluorouracil depsipeptide hepatoma cell Fas apoptosis
分类号 R735.7 [医药卫生—肿瘤]
  • 相关文献

参考文献3

二级参考文献42

  • 1Parkin D M, Bray F, Ferlay J, et al. Estimating the world cancer burden: Globocan 2000[J]. Int J Cancer, 2001,94(2): 153-156.
  • 2Bruix J, Sherman M, Llovet J M, et al. Clinical management of hepatocellular carcinoma:Conclusions of the Barcelona-2000 EASL Conference[J]. J Hepatol,2001,35(2) :421-430.
  • 3Bruix J, Llovet J M. Prognostic prediction and treatment strategy in hepatocellular carcinoma[J]. Hepatology, 2002,35 (3) : 519-524.
  • 4Llovet J M,Fuster J,Bruix J. Intention-to-treat analysis of surgical treatment for early hepatocellular carcinoma: resection versus transplantation[J]. Hepatology, 1999,30(4): 1434- 1440.
  • 5Arii S, Yamaoka Y, Futagawa S, et al. Result of surgical and nonsurgical treatment for small-sized hepatollular carcinoma: A retrospective and nationwide survey in Japan[J]. Hepatology,2000,32(6) :1224-1229.
  • 6Mazzaferro V,Regalia E,Doci R,et al. Liver transplantation for the treatment of small hepatocellular carcinoma in patients with cirrhosis[J]. N Engl J Med, 1996,334(11): 693-699.
  • 7Sarasin F P, Majno P E, Llovet J M,et al. Living donor liver transplantation for early hepatocellular carcinoma:A life-expectancy and cost-effectiveness perspective[J]. Hepatology, 2001,33 (5) :1073-1079.
  • 8Otto G, Heuschen U, Hofmann W J. et al. Survival and recurrence after liver transplantation versus liver resection for hepatocellular carcinoma: a retrospective analysis[J]. Ann Surg, 1998,227(3) :424-432.
  • 9Vilana R,Bruix J,Bru C, et al. Tumor size determines the efficacy of percutaneous ethanol injection for the treatment of small hepatocellular carcinoma[J]. Hepatology, 1992,16 (2) : 353-357.
  • 10Livraghi T,Giorgio A,Marin G,et al. Hepatocellular carcinoma and cirrhosis in 746 patients: Long-term results of percutaneous ethanol injection[J]. Radiology, 1995,197 (1): 101 - 108.

共引文献20

同被引文献22

  • 1Jian-Ming Wang,Bao-Lai Xiao,Jian-Wei Zheng,Hai-Bing Chen,Sheng-Quan Zou.Effect of targeted magnetic nanoparticles containing 5-FU on expression of bcl-2, bax and caspase 3 in nude mice with transplanted human liver cancer[J].World Journal of Gastroenterology,2007,13(23):3171-3175. 被引量：8
  • 2Catherine M. Engelhardt,Karin Bundschu,Marlies Messerschmitt,Thomas Renné,Ulrich Walter,Matthias Reinhard,Kai Schuh.Expression and subcellular localization of Spred proteins in mouse and human tissues[J]. Histochemistry and Cell Biology . 2004 (6)
  • 3Bundschu K,Walter U,Schuh K.Getting a first clue about SPRED functions. Bioessays . 2007
  • 4Miyoshi K,Wakioka T,Nishinakamura H,et al.The Sprouty-related protein,Spred,inhibits cell motility,metastasis,and Rhomediated actin reorganization. Oncegene . 2004
  • 5Liu XY,Yang YF,Wu CT,et al.Spred2 is involved in imatinibinduced cytotoxicity in chronic myeloid leukemia cells. Biochemical and Biophysical Research Communications . 2010
  • 6I. Nobuhisa,R. Kato,H. Inoue,M. Takizawa,K. Okita,A. Yoshimura,T. Taga.Spred-2 suppresses Aorta-Gonad-Mesonephros hematopoiesis by inhibiting MAP Kinase activation. The Journal of Experimental Medicine . 2004
  • 7Lee SA,Ho C,Roy R,Kosinski C,Patil MA,Tward AD,Fridlyand J et al.Integration of genomic analysis and in vivo transfection to identify sprouty 2 as a candidate tumor suppressor in liver cancer. Hepatology . 2008
  • 8Atorrasagasti C,Malvicini M,Aquino J B,et al.Overex-pression of SPARC obliterates the in vivo tumorigenicityof human hepatocellular carcinoma cells. Int J Canc-er . 2010
  • 9T. Wakioka,A. Sasaki,R. Kato,T. Shouda,A. Matsumoto,K. Miyoshi,M. Tsuneoka,S. Komiya,R. Baron,A. Yoshimura.Spred is a Sprouty-related suppressor of Ras signalling. Nature . 2001
  • 10Nonami,A.,Kato,R.,Taniguchi,K.,Yoshiga,D.,Taketomi,T.,Fukuyama,S.Spred-1 negatively regulates interleukin-3-mediated ERK/mitogen-activated protein (MAP) kinase activation in hematopoietic cells. Journal of Biological Chemistry . 2004

引证文献2

二级引证文献3

中南大学学报（医学版）
2009年 第2期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部